Anthony Gibney
Director/Board Member chez INFLARX N.V.
Fortune : 168 400 $ au 31/03/2024
Profil
Anthony S.
Gibney is currently an Independent Non-Executive Director at InflaRx NV, a Director at Clearside Biomedical, Inc., and a Director at LAPIX Therapeutics, Inc. Previously, he held positions as a Director at InflaRx GmbH, Managing Director-Global Healthcare Group at Merrill Lynch & Co., Inc., Independent Non-Executive Director at InflaRx NV, Associate-Healthcare Investment Banking Group at Lehman Brothers, Inc., Chief Business Officer & Executive Vice President at Achillion Pharmaceuticals, Inc., MD & Co-Head-Biotechnology Investment Team at Leerink Partners LLC, Chief Business & Strategy Officer, Executive VP at IVERIC bio, Inc., and Chief Financial & Business Officer at Fog Pharmaceuticals, Inc. Mr. Gibney obtained his undergraduate degree from Yale University in 1993.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 18/04/2024 | 100 000 ( 0,13% ) | 153 000 $ | 31/03/2024 | |
INFLARX N.V.
0,02% | 31/12/2023 | 10 000 ( 0,02% ) | 15 400 $ | 31/03/2024 |
Postes actifs de Anthony Gibney
| Sociétés | Poste | Début |
|---|---|---|
| INFLARX N.V. | Director/Board Member | 19/05/2021 |
| CLEARSIDE BIOMEDICAL, INC. | Director/Board Member | 15/04/2024 |
Lapix Therapeutics, Inc.
 Lapix Therapeutics, Inc. BiotechnologyHealth Technology Lapix Therapeutics, Inc. is a company located in the US that is focused on developing new therapies for autoimmune diseases and oncology. The American company's approach involves creating orally bioavailable immune system restoration therapies that are designed to be effective and easy to use. | Director/Board Member | 01/01/2024 |
Anciens postes connus de Anthony Gibney
| Sociétés | Poste | Fin |
|---|---|---|
| IVERIC BIO, INC. | Corporate Officer/Principal | 01/07/2023 |
Fog Pharmaceuticals, Inc.
 Fog Pharmaceuticals, Inc. BiotechnologyHealth Technology Fog Pharmaceuticals, Inc. develops pharmaceutical products. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane and is headquartered in Cambridge, MA. | Director of Finance/CFO | 01/12/2021 |
| ACHILLION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 28/01/2020 |
| INFLARX N.V. | Director/Board Member | 01/06/2019 |
Leerink Partners LLC
 Leerink Partners LLC Investment Banks/BrokersFinance Leerink Partners LLC is a full-service brokerage and investment banking firm headquartered in Boston, Massachusetts. The firm was founded by Jeffrey Leerink in 1995 and formerly known as SVB Securities LLC. They rebranded as Leerink Partners in 2023. The firm is a subsidiary of SVB Securities LLC. Leerink Partners provides institutional sales, equity research, institutional trading, and corporate finance and asset management services to the healthcare and technology industries. They offer superior execution capabilities in common stock, convertibles and derivatives with a singular focus on healthcare and a knowledge-led approach. | Corporate Officer/Principal | 01/01/2017 |
Formation de Anthony Gibney
| Yale University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| CLEARSIDE BIOMEDICAL, INC. | Health Technology |
| INFLARX N.V. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Lehman Brothers, Inc.
 Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | Finance |
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA. | Health Technology |
Leerink Partners LLC
Leerink Partners LLC Investment Banks/BrokersFinance Leerink Partners LLC is a full-service brokerage and investment banking firm headquartered in Boston, Massachusetts. The firm was founded by Jeffrey Leerink in 1995 and formerly known as SVB Securities LLC. They rebranded as Leerink Partners in 2023. The firm is a subsidiary of SVB Securities LLC. Leerink Partners provides institutional sales, equity research, institutional trading, and corporate finance and asset management services to the healthcare and technology industries. They offer superior execution capabilities in common stock, convertibles and derivatives with a singular focus on healthcare and a knowledge-led approach. | Finance |
IVERIC bio, Inc.
 IVERIC bio, Inc. Pharmaceuticals: GenericHealth Technology IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. | Health Technology |
InflaRx GmbH
 InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. | Health Technology |
| Merrill Lynch & Co., Inc. | Finance |
Fog Pharmaceuticals, Inc.
Fog Pharmaceuticals, Inc. BiotechnologyHealth Technology Fog Pharmaceuticals, Inc. develops pharmaceutical products. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane and is headquartered in Cambridge, MA. | Health Technology |
Lapix Therapeutics, Inc.
Lapix Therapeutics, Inc. BiotechnologyHealth Technology Lapix Therapeutics, Inc. is a company located in the US that is focused on developing new therapies for autoimmune diseases and oncology. The American company's approach involves creating orally bioavailable immune system restoration therapies that are designed to be effective and easy to use. | Health Technology |
